Generate Biomedicines Bolsters Leadership Team With the Addition of Jason Silvers, M.D., J.D., as Chief Financial Officer

Former Goldman Sachs Co-head of EMEA Healthcare Investment Banking, Partner and Managing Director brings extensive experience in corporate biotech and strategic finance

Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, announced that Jason Silvers, M.D., J.D., has been named the company’s Chief Financial Officer, overseeing all financial matters as the company advances into its next stage of growth.

Latest Aithority Insights: AiThority.com to Attend The Character of AI – A Technology Ethics Conference (Virtual)

“We’re thrilled that Jason is joining the Generate Biomedicines team at this exciting time in Generate’s development pioneering generative biology”

Dr. Silvers was at Goldman Sachs for 20 years, where he was named managing director in 2010 and Partner in 2014. Most recently, he was based in London and co-managed healthcare investment banking for Europe, the Middle East and Africa. Previously, he served as the Global Head of Healthcare Mergers & Acquisitions. Over his career, he has completed more than 75 merger and acquisition and financing transactions valued at more than $400 billion.

AI and ML News: AI: Continuing the Chase for Brain-Level Efficiency

“We’re thrilled that Jason is joining the Generate Biomedicines team at this exciting time in Generate’s development pioneering generative biology,” said Mike Nally, Generate’s Chief Executive Officer. “His stellar background, breadth and depth of expertise, including his strategic and transactional experience, are invaluable attributes that will help fuel our growth as we grow our organization to support our ambitious business objectives.”

Dr. Silvers commented, “Generate is revolutionizing drug development through a powerful new approach to making protein therapeutics. With $370 million in Series B funding, a partnership with Amgen, and the extraordinary potential of its technology platform, the company is well-positioned to make history. I am excited to work closely with such a talented team to help advance the company’s computer-generated protein therapeutics.”

He graduated magna cum laude from Brown University with a bachelor’s of science degree in chemistry. He attended the Johns Hopkins University School of Medicine. After medical school, he completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction. He continued his education at Yale Law School, where he earned his juris doctor degree and was editor-in-chief of the Yale Journal of Health Policy, Law, and Ethics.

AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection

[To share your insights with us, please write to sghosh@martechseries.com]